SEATTLE — Subtypes of seizures have improved through the use of cenobamate, William E. Rosenfeld, MD, FAAN, said at the 2022 American Academy of Neurology annual meeting.
“Cenobamate is a drug that was approved by the [FDA] in 2019 … for patients with partial or focal seizure disorders, under the new terminology that would include focal to bilateral tonic-clonic seizures, focal unaware seizures and focal aware seizures,” Rosenfeld, director of The Comprehensive Epilepsy Care Center for Children and Adults in St. Louis, said.